Before a second course is approved over a previously treated region, the team weighs the earlier external beam courses, concurrent chemotherapy, and routine image guidance. Which statement best describes how these contributions should be considered when judging normal tissue tolerance?

Normal-tissue tolerance assessment should include the therapeutic radiation already delivered and the dose planned for the new course, because both contribute to organ-at-risk exposure. Concurrent chemotherapy can modify normal-tissue toxicity, so it belongs in the assessment. Imaging exposure is distinct from therapeutic dose and should be evaluated separately when clinically meaningful, rather than automatically added as if it were treatment. A proposed approach that sums prior and planned therapeutic doses and accounts for chemotherapy but omits image-guidance exposure even when clinically meaningful makes that omission too broad. An approach that includes cumulative therapeutic dose and separately assesses relevant imaging exposure but treats chemotherapy as unrelated to normal-tissue toxicity wrongly excludes a toxicity modifier. An approach that considers the planned course, chemotherapy, and relevant imaging but does not sum earlier therapeutic courses misses the prior exposure needed to judge tolerance in a previously treated region. Exam caveat: cumulative dose may require biologically appropriate conversion and consideration of fractionation, tissue recovery, and uncertainty; simple addition of physical doses may not be adequate. Practical check: retrieve prior treatment plans and dose distributions, confirm relevant organ contours and the current plan, review concurrent systemic therapy, and determine whether imaging exposure is material to the clinical judgment.